Possible role of vascular intima for generation of coagulant activity in patients undergoing coronary thrombolysis with recombinant tissue-type plasminogen activator. A randomized, placebo-controlled study

References

• De Wood M A, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897–902
   PubMed Web of Science ®Google Scholar
• ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected myocardial infarction: ISIS-2. Lancet 1988; ii: 349–60
   Google Scholar
• ASSET Study Group. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988; ii: 525–30
   Google Scholar
• Chesebro J H, Knatterud G, Roberts R, et al. Thrombolysis in myocardial (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142–54
   PubMed Web of Science ®Google Scholar
• Owen J, Friedman K D, Grossman B A, et al. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988; 72: 616–20
   PubMed Web of Science ®Google Scholar
• Seitz R, Blanke H, Prätorius G, Strauer B E, Egbring R. Increased thrombin activity during thrombolysis. Thromb Haemost 1988; 59: 541–2
   PubMed Web of Science ®Google Scholar
• Eisenberg P R, Sherman L A, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intensive fibrinolysis. J Am Coll Cardiol 1987; 10: 527–9
   PubMed Web of Science ®Google Scholar
• Fulton W FM. The morphology of coronary thrombotic occlusions relevan T to thrombolytic intervention. Transluminal coronary angioplasty and intracoronary thrombosis, M Kaltenbach, A Grüntzig, K Rentrop, WD Bussmann. Springer-Verlag, Berlin 1982; 244–52
   Google Scholar
• Francis C W, Connaghan G, Scott W L, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation 1987; 75: 1170–7
   PubMed Web of Science ®Google Scholar
• Brenner B, Francis C W, Totterman S, et al. Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation 1990; 81: 1818–25
   PubMed Web of Science ®Google Scholar
• Weiss H J, Turitto V T, Baumgartner H R, Nemerson Y, Hoffmann T. Evidence for the presence of tissue factor activity on subendo-thelium. Blood 1989; 73: 968–75
   PubMed Web of Science ®Google Scholar
• Stern D, Nawroth P, Handley D, Kisiel W. An endothelial cell-dependent pathway of coagulation. Proc Natl Acad Sci USA 1985; 82: 2523–7
   PubMed Web of Science ®Google Scholar
• Munkvad S, Gram J, Jespersen J, Grande P. Reduction of infarct size estimated enzymatically in patients with acute myocardial infarction after treatment with tissue-type plasminogen activator or after spontaneous recanalization: a randomized, placebo-controlled study. Fibrinolysis 1990; 4: 95–9
   Google Scholar
• Nomenclature and criteria for diagnoses of ischemic heart disease. Report of the Joint Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Circulation 1979; 59: 607–8
   PubMed Web of Science ®Google Scholar
• Jespersen J, Knudsen L H, Sidelmann J. The use of evacuated glass tubes for collection of blood samples for fibrinolytic assays. Thromb Res 1982; 25: 173–6
   PubMed Web of Science ®Google Scholar
• Kettner C, Shaw E. D-Phe-Pro-Arg-CH2CI-a selective affinity label for thrombin. Thromb Res 1979; 14: 969–73
   PubMed Web of Science ®Google Scholar
• Lijnen H R, Uytterhoeven M, Collen D. Inhibition of trypsin-like serine proteases by tripeptide arginyl and lysyl chloromethylketones. Thromb Res 1984; 34: 431–7
   PubMed Web of Science ®Google Scholar
• Koppert P, Hogee-de Nobel B, Nieuwenhuizen W. Monoclonal antibody based enzyme immunoassay for fibrin degradation in plasma. Thromb Haemost 1988; 59: 310–5
   PubMed Web of Science ®Google Scholar
• Pelzer H, Stiiber W. Activation products of coagulation proenzymes as markers of hypercoagulability. 6. Kongress der Gesellschaft fur Thrombose- und Hämostase-forschung, HD Bruhn. Schattauer, Stuttgart 1990; 100–4
   Google Scholar
• Pelzer H, Schwartz A, Heimburger N. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101–6
   PubMed Web of Science ®Google Scholar
• Bauer KA. Activation peptides of haemostatic system zymogens as markers of hypercoagulability. 6. Kongress der Gesellschaft für Thrombose- und Hämostaseforschung, HD Bruhn. Schattauer, Stuttgart 1990; 98–9
   Google Scholar
• Gram J, Jespersen J. A functional plasminogen assay utilizing the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samples. Thromb Haemost 1985; 53: 255–9
   PubMed Web of Science ®Google Scholar
• Duguid JB. Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J Pathol 1948; 60: 57–61
   Web of Science ®Google Scholar
• Seifried E, Tanswell P, Rijken D C, Kluft C, Hoegee E, Nieuwenhuizen W. Fibrin degradation products are not specific markers for thrombolysis in myocardial infarction. Lancet 1987; 2: 333–4
   PubMed Web of Science ®Google Scholar
• Munkvad S, Jespersen J, Gram J, Kluft C. Long-lasting depression of Factor XII-dependent fibrinolytic activity in patients with myocardial infarction undergoing thrombolytic therapy with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1991; 17: 957–62
   PubMed Web of Science ®Google Scholar
• Jespersen J. Pathophysiology and clinical aspects of fibrinolysis and inhibition of coagulation. Experimental and clinical studies with special reference to women on oral contraceptives and selected groups of thrombosis prone patients. Dan Med Bull 1988; 35: 1–33
   PubMed Web of Science ®Google Scholar
• Rosenberg R D, Rosenberg JS. Natural anticoagulant mechanisms. J Clin Invest 1984; 74: 1–6
   PubMed Web of Science ®Google Scholar
• Serneri G GN, Gensini G F, Carnovali M, et al. Effectiveness of low-dose heparin in prevention of myocardial infarction. Lancet 1987; i: 937–42
   Google Scholar
• The SCATI group. Randomised controlled trial of subcutaneous calcium heparin in acute myocardial infarction. Lancet 1989; ii: 182–6
   Google Scholar
• Mirshahi M, Soria J, Soria C, et al. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 1989; 74: 1025–30
   PubMed Web of Science ®Google Scholar
• Farstad I N, Nielsen D WT, Ruyter R, Godal HC. Thrombin activity in pulmonary emboli obtained at autopsy. Thromb Res 1990; 59: 879–82
   PubMed Web of Science ®Google Scholar
• Grande P, Hansen B F, Christiansen C, Naestoft J. Estimation of acute myocardial infarct size in man by serum CK-MB measurements. Circulation 1982; 65: 756–64
   PubMed Web of Science ®Google Scholar
• van Hulsteijn H, Kolff J, Briët E, van der Laarse A, Bertina R. Fibrinopeptide A and beta thromboglobulin in patients with angina pectoris and acute myocardial infarction. Am Heart J 1984; 107: 39–45
   PubMed Web of Science ®Google Scholar
• Gastone G, Serneri G GN, Gensini GF, et al. Association between time of increased fibrinopeptide A levels in plasma and episodes of spontaneous angina: a controlled prospective study. Am Heart J 1987; 113: 672–8
   PubMed Web of Science ®Google Scholar
• Thèroux P, Latour J-G, Løger-Gauthier C, De Lara J. Fibrinopeptide A and platelet factor levels in unstable angina pectoris. Circulation 1987; 75: 156–62
   PubMed Web of Science ®Google Scholar
• Irie T, Imaizumi T, Matuguchi T, et al. Increased fibrinopeptide A during anginal attacks in patients with variant angina. J Am Coll Cardiol 1989; 14: 589–94
   PubMed Web of Science ®Google Scholar
• Ogawa H, Yasue H, Oshima S, Okumura K, Matsuyama K, Obata K. Orcadian variation of plasma fibrinopeptide A level in patients with variant angina. Circulation 1989; 80: 1617–26
   PubMed Web of Science ®Google Scholar
• Munkvad S, Jespersen J, Gram J, Kluft C. Interrelationship of coagulant activity and tissue-type plasminogen activator (t-PA) system in acute heart disease. Possible role of the endothelium. J Intern Med 1990; 228: 361–6
   PubMed Web of Science ®Google Scholar